ImmunotherapySublingual grass allergen tablet immunotherapy provides sustained clinical benefit with progressive immunologic changes over 2 years
Section snippets
Clinical trial design
A randomized, parallel-group, double-blind, placebo-controlled, multicenter trial was performed. The trial is an extension of a previously published trial in which participants received double-blind treatment from the autumn of 2004 until the end of the grass pollen season of 2005.14 Three hundred fifty-one participants from 43 sites in 7 countries continued treatment with grass allergen tablets or placebo and will continue treatment until the end of the grass pollen season of 2007. The
Results
Five hundred forty-six participants completed the first year of the trial. Because of closure of a few trial centers, only 472 could be offered to continue in the extension. Three hundred fifty-one accepted participation in the extension period of the trial and continued doubled-blind treatment after the grass pollen season of 2005. A diagram of the trial flow is presented in Fig 1. Three hundred nineteen participants were in the trial when the grass pollen season of 2006 started, and 306 were
Discussion
The present data are from an extension of a trial in which approximately 65% of completers from the original trial chose to continue double-blinded treatment during the extension. Different analyses were performed to investigate whether the population that continued in the extension of the trial was representative for the entire population during the first year of the trial. The analyses demonstrated that both demographics and symptom and medication scores for the first year of treatment were
References (31)
Impact of upper respiratory allergic diseases on quality of life
J Allergy Clin Immunol
(1998)- et al.
Pollen immunotherapy reduces the development of asthma in children with seasonal rhinoconjunctivitis (the PAT-study)
J Allergy Clin Immunol
(2002) - et al.
Coseasonal sublingual immunotherapy reduces the development of asthma in children with allergic rhinoconjunctivitis
J Allergy Clin Immunol
(2004) - et al.
Efficacy and safety of sublingual immunotherapy with grass allergen tablet for seasonal allergic rhinoconjunctivitis
J Allergy Clin Immunol
(2006) - et al.
Sublingual immunotherapy with once-daily grass allergen tablets: a randomized controlled trial in seasonal allergic rhinoconjunctivitis
J Allergy Clin Immunol
(2006) - et al.
Performance evaluation of a specific IgE assay developed for the ADVIA centaur immunoassay system
Clin Biochem
(2004) - et al.
Allergic rhinitis and its impact on asthma
J Allergy Clin Immunol
(2001) - et al.
Validation of the standardized version of the Rhinoconjunctivitis Quality of Life Questionnaire
J Allergy Clin Immunol
(1999) - et al.
Mechanisms of immunotherapy
J Allergy Clin Immunol
(2004) - et al.
Efficacy and safety of specific immunotherapy with SQ allergen extract in treatment-resistant seasonal allergic rhinoconjunctivitis
J Allergy Clin Immunol
(2006)
Update on sublingual immunotherapy
Ann Allergy Asthma Immunol
Prevalence and rate of diagnosis of allergic rhinitis in Europe
Eur Respir J
Symptom control in patients with hay fever in UK general practice: how well are we doing and is there a need for allergen immunotherapy?
Clin Exp Allergy
WHO Position Paper. Allergen immunotherapy: Therapeutic vaccines for allergic diseases
Allergy
Grass pollen immunotherapy: efficacy and safety during a 4-year follow-up study
Allergy
Cited by (172)
Disease-Modifying Effect of Japanese Cedar Pollen Sublingual Immunotherapy Tablets
2021, Journal of Allergy and Clinical Immunology: In PracticeImmunological Responses and Biomarkers for Allergen-Specific Immunotherapy Against Inhaled Allergens
2021, Journal of Allergy and Clinical Immunology: In PracticeCitation Excerpt :Measurement of immunoreactive levels of serum allergen-specific antibodies during immunotherapy has shown a consistent increase, although, in general, these markers have reflected only the exposure to high levels of allergen during immunotherapy and correlated poorly with the clinical response to treatment. For example, a paradoxical transient early increase in the level of peripheral blood allergen-specific IgE84,85 is reproducibly shown during AIT with whole allergen extracts and appears particularly marked with the sublingual route of treatment.86 This neither correlates with improvement nor is it associated with adverse side effects.
Mucosal IgE immune responses in respiratory diseases
2019, Current Opinion in PharmacologyMechanisms of allergen immunotherapy for inhaled allergens and predictive biomarkers
2017, Journal of Allergy and Clinical ImmunologyTolerability of the SQ Tree SLIT Tablet in Adults
2017, Clinical Therapeutics
Sponsored by ALK-Abelló A/S, Hørsholm, Denmark.
Disclosure of potential conflict of interest: A. Kapp is on the speakers' bureau for ALK-Abelló, UCB, Novartis, and Astella. B. Riis is employed by ALK-Abelló. S. R. Durham has consulting arrangements and has received grant support from ALK-Abelló and GlaxoSmithKline and is on the speakers' bureau for ALK-Abelló, GlaxoSmithKline, and Allergy Therapeutics. The rest of the authors have declared that they have no conflict of interest.